Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Cancer. 2010 Mar 22;10:104. doi: 10.1186/1471-2407-10-104.

Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.

Author information

1
Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland. sally.jarvela@sci.fi

Abstract

BACKGROUND:

Peroxiredoxins (Prxs) have recently been suggested to have a role in tumorigenesis.

METHODS:

We studied the expression of Prx I-VI and their relationship to patient survival in 383 grade II-IV diffuse astrocytic brain tumors.

RESULTS:

Prx I positivity was found in 68%, Prx II in 84%, Prx III in 90%, Prx IV in 5%, Prx V in 4% and Prx VI in 47% of the tumors. Prx I and Prx II expression decreased significantly with increasing malignancy grade (p < 0.001 and p < 0.001). Patients with Prx I or Prx II positive tumors were significantly younger than the average age of all the patients (p = 0.014 and p = 0.005). A lower proliferation rate was associated with Prx I and Prx VI positive tumors (p = 0.019 and p = 0.033), and a lower apoptotic rate was found within Prx I and Prx II positive tumors (p < 0.001 and p = 0.007). Patients with Prx I and Prx II positive tumors had a significantly better survival rate than their Prx-negative counterparts (p = 0.0052 and p = 0.0002).

CONCLUSION:

The expression of Prx I and Prx II correlates with astrocytic tumor features, such as grade and patient age and proliferation activity (Prx I), and accordingly with patient survival.

PMID:
20307276
PMCID:
PMC2858108
DOI:
10.1186/1471-2407-10-104
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center